Loading clinical trials...
Loading clinical trials...
A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study With a 36-Week Extension to Investigate the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Despite Treatment With Topical Medications (The HILLIER Study)
Conditions
Interventions
Benralizumab
Placebo / Benralizumab
Locations
51
United States
Research Site
Los Angeles, California, United States
Research Site
Newport Beach, California, United States
Research Site
Bridgeport, Connecticut, United States
Research Site
Fort Myers, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Tampa, Florida, United States
Start Date
November 12, 2020
Primary Completion Date
April 25, 2022
Completion Date
September 13, 2022
Last Updated
August 31, 2023
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions